Mark W. Frohlich
Chief Executive Officer at Indapta Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Pamela Reilly Contag | M | 66 |
BioEclipse Therapeutics, Inc.
 BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | - |
| Gregory Schiffman | M | 67 |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | 16 years |
| Guy DiPierro | M | - |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 7 years |
| Todd Binder | M | - |
Neuvogen, Inc.
| - |
| Kendall Mohler | M | 68 |
Neuvogen, Inc.
| 5 years |
| Ari Helenius | M | - |
Yale University
| 41 years |
| Ronald Martell | M | 62 |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 7 years |
| Mahmoud Mahmoudian | M | - |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | 2 years |
| Sahil Chopra | M | - |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 2 years |
| Laura Stoppel | M | 38 |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 2 years |
| Oliver Hopkinson | M | - |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | 5 years |
| Elona Baum | F | - |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | 5 years |
| Michael C. Gibson | M | - |
Harvard Medical School
| 37 years |
| Biao He | M | - |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | - |
| Lori Hu | F | 38 |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 2 years |
| Gordon Binder | M | 88 |
Neuvogen, Inc.
| - |
| Catherine Sohn | M | 71 |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | 8 years |
| Nicole Keith | F | - | 9 years | |
| Ran Nussbaum | M | 51 |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | - |
| Jim Weiss | M | - |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | 3 years |
| Denny Lanfear | M | 68 |
Neuvogen, Inc.
| - |
| Gregory Verdine | M | 65 |
Harvard Medical School
| 35 years |
| George Demetri | M | 67 |
Harvard Medical School
| 36 years |
| Joseph A. Madri | M | 80 |
Yale University
| 44 years |
| Fady Malik | M | 59 |
The University of California, San Francisco
| 24 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mitchell Gold | M | 57 | 12 years | |
| John Johnson | M | 66 | 3 years | |
| Marc Tessier-Lavigne | M | 64 |
The University of California, San Francisco
| 13 years |
| Robert L. Crotty | M | 50 | 3 years | |
| Robert L. Kirkman | M | 75 |
Xcyte Therapies, Inc.
| 2 years |
| Gregory R. Cox | M | 58 | 10 years | |
| Matt Greenfield | M | - |
Yale University
| 16 years |
| Thomas Daniel | M | 70 | 3 years | |
| Aaron Kaslow | M | 59 |
Yale University
| 7 years |
| W. Lewis Johnson | M | - |
Yale University
| 5 years |
| Harry Ballan | M | - |
Yale University
| 8 years |
| Robert D. Wilder | M | - |
Yale University
| 4 years |
| Bart H. Williams | M | - |
Yale University
| 3 years |
| Joanna Lin Black | F | - |
Xcyte Therapies, Inc.
| 3 years |
| Mark Rosenblatt | M | 65 |
Yale University
| 7 years |
| William J. Schnoor | M | - |
Yale University
| 7 years |
| Michael Joseph Chren | M | - |
Yale University
| 4 years |
| Miguel A. Rodriguez | M | 71 |
Yale University
| 4 years |
| Christine Cvijic | F | 46 | - | |
| Jeffrey S. Haber | M | - |
Yale University
| 7 years |
| Hal Barron | M | 62 | 4 years | |
| Robert S. Poulton | M | 67 | 3 years | |
| Mark Nydam | M | - |
Yale University
| 5 years |
| Gerardo Canet | M | 78 | 17 years | |
| John W. Campbell | M | - |
Yale University
| 3 years |
| Martin A. Steele | M | - |
Yale University
| 1 years |
| Christopher Henney | M | 83 |
Xcyte Therapies, Inc.
| - |
| Robert Glaser | M | 62 |
Yale University
| 4 years |
| Joseph Gleberman | M | 66 |
Yale University
| 4 years |
| Maggie Wilderotter | F | 69 | 4 years | |
| Pedro Granadillo | M | 77 | 5 years | |
| Jon Kayyem | M | 60 |
Yale University
| 5 years |
| James Attwood | M | 65 |
Yale University
| 5 years |
| David Stump | M | 74 | 5 years | |
| Jay Flatley | M | 71 | 1 years | |
| Dean J. Takahashi | M | - |
Yale University
| 5 years |
| Dennis Fenton | M | 72 | 4 years | |
| Richard F. Hamm | M | 64 | 7 years | |
| Cheryl Irene Smith | M | - |
Yale University
| 7 years |
| David F. Swensen | M | 70 |
Yale University
| 4 years |
| John E. Osborn | M | 66 | 1 years | |
| Ron J. Cozean | M | - |
Yale University
| 10 years |
| Peter Salovey | M | 66 |
Yale University
| 5 years |
| David Ezra Gerstenhaber | M | 63 |
Yale University
| 3 years |
| Kiyohiko Nishimura | M | 71 |
Yale University
| 3 years |
| Timothy Lewis | M | - |
Yale University
| 4 years |
| Thomas F. Long | M | - |
Yale University
| 4 years |
| Kristian Hammond | M | - |
Yale University
| 3 years |
| Joseph G. Greenberg | M | 63 |
Yale University
| 4 years |
| Peter Chen | M | 64 |
Yale University
| 3 years |
| Peter B. Pope | M | - |
Yale University
| 3 years |
| Valerie Odegard | M | 46 | 2 years | |
| Lawrence A. Birnbaum | M | - |
Yale University
| 3 years |
| Bob Savage | M | - |
Yale University
| 4 years |
| James Connaughton | M | 62 |
Yale University
| 4 years |
| Mei-June Liao | M | 72 |
Yale University
| 3 years |
| Chris Clark | M | 58 |
Yale University
| 4 years |
| Daniel Rowen | M | - |
Yale University
| 1 years |
| Jim Goff | M | - |
Yale University
| 4 years |
| Andrew L. May | M | 65 |
Yale University
| 4 years |
| Gilbert Andrew Garcia | M | 60 |
Yale University
| 4 years |
| Joe Jolson | M | 65 |
Yale University
| 4 years |
| Winthrop T. Smith | M | - |
Yale University
| 4 years |
| Catherine S. Gallagher | F | - |
Yale University
| 4 years |
| Thomas E. Molner | M | - |
Yale University
| 4 years |
| Perry H. Braun | M | - |
Yale University
| 4 years |
| David Segel | M | 60 |
Yale University
| 4 years |
| Keith S. Crow | M | - |
Yale University
| 4 years |
| Kevin Lewis | M | - |
Yale University
| 4 years |
| David S. McCarthy | M | - |
Yale University
| 4 years |
| R. David Franklin | M | - |
Yale University
| 4 years |
| Woo Chan Lee | M | - |
Yale University
| 4 years |
| John F. Pergande | M | - |
Yale University
| 4 years |
| David A. Tewksbury | M | 63 |
Yale University
| 4 years |
| Howard A. Kenny | M | - |
Yale University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark W. Frohlich
- Personal Network
